FRASE-bot screening identifies a small-molecule ligand that selectively kills CIB1-dependent cancer cells
FRASE-bot used a neural-network nativeness score to triage protein–ligand fragments, then used the retained structural features to seed virtual screening for Calcium and Integrin Binding Protein 1 (CIB1). Of 56 purchased virtual-screen hits, 29 showed dose-dependent CIB1 displacement; compound UNC10245380 (UNC5380) had a TR-FRET displacement IC50 of 8.0 ± 2.5 μM and selectively killed CIB1-depletion-sensitive triple-negative breast cancer cells in the reported assays, with no detected killing in an insensitive line.
Technology: FRASE-bot: fragment-in-structural-environment screening with a neural-network nativeness scoring model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of 56 purchased virtual-screen hits, 29 showed dose-dependent CIB1 displacement; compound UNC10245380 (UNC5380) had a TR-FRET displacement IC50 of 8.0 ± 2.5 μM and selectively killed CIB1-depletion-sensitive triple-negative breast cancer cells in the reported assays, with no detected killing in an insensitive line.
- Still unknown: The authors describe UNC10245380 as a starting chemical probe/lead, not a drug. Binding was inferred from peptide displacement in TR-FRET and a docking pose; the pose is not a solved small-molecule complex. Selective cell killing was in vitro at 30 μM, with no animal or clinical evidence. The earlier Research Square manuscript is the same underlying paper/result and is not counted separately.
- AI role: The neural network triaged fragments by predicted native-ligand pose likelihood; selected fragments informed pharmacophore construction and virtual screening. The resulting purchased compounds were then tested in TR-FRET binding-displacement and cell-death assays. The model did not perform the wet-lab validation.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11219766/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 14 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.